Company news
Twist Bioscience Corporation (NASDAQ:TWST) news
Twist Bioscience Corporation news releases on 6ix. Latest, Feb 28, 2022: Twist Bioscience Becomes Digital Preservation Coalition Supporter
Press releases — page 4
Twist Bioscience Becomes Digital Preservation Coalition Supporter
February 27, 2022
Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 14, 2022
Twist Bioscience to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
Twist Bioscience Announces Pricing of an Upsized $250 Million Public Offering of Common Stock
February 9, 2022
Twist Bioscience Announces Proposed Public Offering of Common Stock
February 8, 2022
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools
February 6, 2022
Twist Bioscience Reports First Quarter 2022 Financial Results
February 3, 2022
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
January 31, 2022
Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
January 30, 2022
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
January 24, 2022
Twist Bioscience to Report Fiscal 2022 First Quarter Financial Results on Friday, February 4, 2022
January 19, 2022
Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference
January 9, 2022
Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research
January 5, 2022
Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants
January 4, 2022
Twist Bioscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing
December 19, 2021
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
December 14, 2021
Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays
December 6, 2021
Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors
November 29, 2021
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results
November 21, 2021
Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities
November 21, 2021
Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs
November 17, 2021
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
November 14, 2021
Twist Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
November 8, 2021
Twist Bioscience Named in Inc.’s First Annual Best-Led Companies List
November 1, 2021
Twist Bioscience to Report Fiscal 2021 Fourth Quarter and Full Year Financial Results on Monday, November 22, 2021
October 31, 2021
Twist Bioscience Launches Exome 2.0 for Genomics Research
October 19, 2021
Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
October 12, 2021
Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage
October 11, 2021
Twist Bioscience Expands Expert Custom Alliance Panel Offering
October 4, 2021
Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer
September 26, 2021
Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results
August 5, 2021
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Delta (B.1.617.2) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
July 21, 2021
Twist Bioscience to Report Fiscal 2021 Third Quarter Financial Results on Friday, August 6, 2021
July 20, 2021
Twist Bioscience Acquires NGS Library Preparation Maker iGenomX
June 29, 2021
Twist Bioscience Begins Shipping of Synthetic RNA Controls for Kappa (B.1.617.1) SARS-CoV-2 Variants for Development of Accurate Tests
June 7, 2021
Twist Bioscience Launches Enzymatic Fragmentation Library Preparation Kit for High Uniformity, High-Yield Amplification, Streamlined Next Generation Sequencing Workflow for Targeted Applications
May 24, 2021
Twist Bioscience Supports the Engineering Biology Research Consortium as it Publishes Statement of Ethics
May 12, 2021
Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results
May 5, 2021
Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021
April 21, 2021
Twist Bioscience to Expand Oregon Lease, Supporting Future Growth
April 15, 2021
Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software
April 11, 2021
Twist Bioscience Earns 2021 Great Place to Work Certification™
April 4, 2021
Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
March 24, 2021
Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay
March 23, 2021
Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants
March 14, 2021
Twist Bioscience Launches Industry-Leading NGS Methylation Detection System for Liquid Biopsy Cancer Analysis and Epigenetic Studies
February 23, 2021
Twist Bioscience and Victorian Clinical Genetic Services Collaborate on Development of Novel Whole Exome Capture Diagnostic Assay
February 17, 2021
Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results
February 3, 2021
Twist Bioscience Announces Executive Team Appointments
February 2, 2021